Reading PCSA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PCSA free→Reading PCSA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PCSA free→QuarterlyIQ Insights · PCSA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement. Effective May 1, 2026, Dr. Bigora will transition from a full-time executive officer role to a part-time emp…
Termination of a Material Definitive Agreement. On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation. Neither party to the Term Sheet has any additional obligations under the agreement following its expiration.
Material Modification to Rights of Security Holders To the extent required by
Unregistered Sales of Equity Securities The matters described in
Entry into a Material Definitive Agreement. On August 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreement”) for a private placement with an accredited investor wherein the Company sold 5,467,181 restricted shares of common stock at a purchase price of $0.23 per share for approximately $1.3 million in gross proceeds (the “Offering”), before deducting Placement Agent fees and other expenses related to the Offeri…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. As previously disclosed on Form 8-K filed on February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requiremen…
Entry into a Material Definitive Agreement. On August 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreement”) for a private placement with an accredited investor wherein the Company sold 5,467,181 restricted shares of common stock at a purchase price of $0.23 per share for approximately $1.3 million in gross proceeds (the “Offering”), before deducting Placement Agent fees and other expenses related to the Offeri…
Unregistered Sales of Equity Securities The matters described in
Other Events. On July 25, 2025, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Securities and Exchange Commission a prospectus supplement to its Registration Statement on Form S-3 (Registration No. 333-279588) permitting the Company to sell $5,239,073 shares of the Company’s common stock pursuant to its equity distribution agreement with A.G.P. / Alliance Global Partners. As of the date of the prospectus supplement, the Company had offered and sold $1,546,338 shares of the Comp…
Entry into a Material Agreement. On June 27, 2025, Processa Pharmaceuticals, Inc. (the “Company”) invoked its right to terminate the Licensing Agreement between Ocuphire Pharma, Inc., (now Opus Genetics) dated June 16, 2021.
Entry into a Material Agreement. On June 24, 2025, Yuhan executed Amendment No. 1 to the Yuhan agreement with such amendment being effective as of June 11, 2025. The Amendment was in connection with the entry into the term sheet, on June 17, 2025 with Intact Therapeutics.
Entry into a Material Definitive Agreement. On June 17, 2025, Processa Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreement”) with accredited investors pursuant to which the Company sold, in a best efforts registered public offering (the “Offering”), (i) 14,310,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) Pre-Funded Warrants to purchase up to 13,690,000 shares of…
Entry into a Material Agreement. On June 17, 2025, Processa Pharmaceuticals, Inc. (the “Company”) entered into a Binding Term Sheet (the “Term Sheet”) with Intact Therapeutics. (“Intact”), granting Intact the exclusive option to license PCS12852, a highly specific and potent 5HT4 agonist that is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients. Upon execution of the Term Sheet, the Company received a non-refundable standstill payment of $20,000…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. On February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capi…
Entry into a Material Definitive Agreement. On January 27, 2025, Processa Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with a healthcare focused institutional investor pursuant to which the Company agreed to sell and issue, in a reasonable best efforts registered public offering (the “Offering”), (i) 1,030,972 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) S…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'None' to 'mixed'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.